1. Introduction {#sec1-ijerph-13-01000}
===============

Many rural communities have poor access to health services due to a combination of distance from specialist services and a relative shortage of general practitioners. These disadvantages can lead to differences in health outcomes. Breast cancer is the most commonly diagnosed cancer in New Zealand (NZ) women with 3000 new cases each year. It is also an important cause of death with 617 deaths per year \[[@B1-ijerph-13-01000]\]. Urban rural differences in breast cancer are well known. A comprehensive systematic review of the international literature suggested rural women were 19% more likely to be diagnosed with advanced stage at diagnosis \[[@B2-ijerph-13-01000]\]. Differences in mortality have also been shown between urban and rural women with breast cancer in Scotland \[[@B3-ijerph-13-01000]\], South Australia \[[@B4-ijerph-13-01000]\] and Germany \[[@B5-ijerph-13-01000]\]. It is difficult to generalise the findings from international studies as the definition of rurality can vary. For instance rural and remote communities in Australia and Canada will involve much greater distances from an urban medical centre than would be the case in Europe where population densities are greater.

In New Zealand, differences have been shown in the presentation and outcomes of breast cancer for Māori and Pacific women compared with NZ Europeans \[[@B6-ijerph-13-01000],[@B7-ijerph-13-01000]\]. A prior study using NZ cancer registry data did not show differences in breast cancer mortality or stage of diagnosis for urban versus rural women after adjustment for age, ethnicity and socioeconomic status \[[@B8-ijerph-13-01000]\]. However the NZ cancer registry data has missing data and limited information on other characteristics that may influence outcomes, and the missing data may be differential by urban/rural status. For example, it may be that those living in more rural areas are more likely to have data missing. There is also variation in the definition of what is considered a rural population. This study is based on substantially more detailed clinical data available (including accurate staging, screening history and presence of biological markers) from two clinical breast cancer registers in the Waikato and Auckland regions \[[@B9-ijerph-13-01000]\]. Waikato District Health Board has a large rural community with 60% of patients living outside the main centre of Hamilton, while Auckland on the other hand is mainly an urban community. Our aims were (1) to compare the differences and characteristics of rural women particularly stage of diagnosis and tumour size as these are important measures of differences in diagnosis; (2) to assess breast cancer-specific and all-cause survival for urban and rural women with breast cancer; and (3) to assess whether the impact of rurality is different for Māori and NZ European women in New Zealand.

2. Methods {#sec2-ijerph-13-01000}
==========

The population for this study included all women diagnosed with invasive breast cancer in the Waikato and Auckland regions from June 2000 to May 2013. The two registers have been collecting data prospectively on newly diagnosed women with breast cancer and have accurate data on demographic characteristics including place of domicile as well as clinical data on the breast cancer at diagnosis and subsequent treatment. Ethical approval for this study was obtained from the New Zealand Northern "A" Health and Disability Ethics Committee (Ref. No. 12/NTA/42).

The definition of urban and rural varies considerably across different studies and countries. Within NZ a number of different definitions have been considered \[[@B10-ijerph-13-01000],[@B11-ijerph-13-01000]\]. For this study we have taken the seven different classifications of the urban rural profile classification basis of NZ statistics which is based on both domicile and work place. The seven categories are Major Urban; Satellite Urban; Independent Urban; Rural with high urban influence; Rural with moderate urban influence; Rural with low urban influence and Highly Rural/Remote. We have categorised rural areas with high urban influence to be urban as these communities generally are the high socioeconomic population living close to urban centres where these families work, shop and receive health care. On the other hand the NZ independent urban centres are those independent towns where general practitioners are classified as being rural and receive a rural bonus. Consequently we have redefined urban as either a major or satellite urban community or communities of high urban influence. Rural we have considered to be independent urban communities or those designated rural with moderate or low or no urban influence.

Other variables included in the study were: age (\<40, 40--49, 50--59, 60--69, 70--79, 80+ years), ethnicity (NZ European, Māori, Pacific, Asian, others), cancer stage (I, II, III, IV), grade (1, 2, 3), tumour size (0--10, 10--20, 20--30, 30--50, 50+ mm), mode of detection (screen detected, not screen detected), and hormone status (Estrogen receptor (ER) and progesterone receptor (PR) negative, ER and/or PR positive). We first compared the characteristics between urban and rural women, and then compared urban and rural Māori and NZ European women. Key demographic and disease characteristics were described for the total cohort, for urban and rural populations and stratified by ethnicity.

Mortality information including date of death and cause of death were from both the combined registers and the Mortality Collection in New Zealand. For all-cause survival analyses, patients without mortality information were considered to be censored on the last updated date for Mortality Collection which was 31 December 2014. For cancer-specific analyses, deaths from other causes were censored on the date of death. Cancer-specific and all-cause survival were assessed for rural and urban women at 5 and 10 years using Kaplan--Meier method. Models were fitted using Cox proportional hazards models with cancer-specific and all-cause deaths as outcomes of interests, to compare outcomes for rural compared with urban women for the whole cohort and stratified by ethnicity. The proportional hazards assumption was tested for both breast cancer-specific and total mortality by creating a time-dependent covariate as an interaction term between urban-rural residence and survival time. The survival difference between subgroups was considered significant if the *p*-value was less than 0.05. All data analyses were performed in SPSS (IBM Corporation, New York, NY, USA).

3. Results {#sec3-ijerph-13-01000}
==========

There were 12,372 women on the two registers with a diagnosis of invasive breast cancer. 2364 were classified as rural, living in an independent rural centre or a rural community, and 9885 were classified as urban (in 123 women domicile was not classified). When comparing the characteristics of urban and rural women with breast cancer, rural women tended to be older and were more likely to be Māori ([Table 1](#ijerph-13-01000-t001){ref-type="table"}). Stage of disease at diagnosis was similar and tumour size was also similar with 51.7% of rural women having a tumour size less than 20 mm and 50.3% of urban women (*p* = 0.238).

When we stratified by ethnicity, we find that rural Māori tended to be older, more likely to be diagnosed with metastatic breast cancer (*p* \< 0.01) and less likely to be screen detected than urban Māori ([Table 2](#ijerph-13-01000-t002){ref-type="table"}). Rural NZ European were older and less likely to be diagnosed with Grade 3 cancer, but otherwise they had similar characteristics to urban NZ European including similar screen detected rates and similar stage at diagnosis.

When comparing 5-year and 10-year survival for urban versus rural women, we found that breast cancer survival is very similar for urban and rural women overall, but that for Māori women survival appears to be worse for rural compared with urban women ([Table 3](#ijerph-13-01000-t003){ref-type="table"}). Rural Māori women had inferior breast cancer-specific survival at 10 years at 72.1% compared to 77.9% for urban Māori (*p* = 0.072). The 5-year and 10-year all-cause survival was 71.6% and 55.8% for rural Māori women compared to 77.9% and 64.9% for urban Māori women (*p* = 0.017).

The hazard ratios for mortality using the Cox proportional hazards model ([Table 4](#ijerph-13-01000-t004){ref-type="table"}) showed that rural NZ European women have similar breast cancer-specific mortality and all-cause mortality compared to urban NZ European women after adjustment for age, cancer stage, tumour size, grade, hormonal status (ERPR), year of diagnosis, mode of detection and comorbidity. However, survival was poorer for rural Māori women compared with urban Māori women for both cancer-specific and all-cause survival. The unadjusted hazard ratio for breast cancer-specific mortality and the all-cause mortality for rural Māori compared with urban Māori was 1.31 (95% CI 0.97--1.76) and 1.33 (95% CI 1.05--1.68), respectively. The hazard ratio increased to 1.47 (95% CI 1.00--2.16) and 1.43 (95% CI 1.08--1.91), respectively, after adjustment for other factors. The proportionality assumption was tested for each of the 6 models shown in [Table 4](#ijerph-13-01000-t004){ref-type="table"}, with no significant departure from proportionality shown in all models except that of all rural versus all urban women for total mortality, where there was significant evidence of interaction between urban-rural residence and survival time on the hazard ratio (*p* = 0.029).

4. Discussion {#sec4-ijerph-13-01000}
=============

The key findings from this study is that there is no evidence that rural women in New Zealand are more likely to present with advanced stage of disease or have poorer outcomes. In our two regions it appears that rural women with breast cancer are older than urban women and that there are proportionately more rural Māori than urban Māori. The cancer-specific mortality rates for rural women were similar suggesting that access to breast cancer treatment is at least as good for rural women as urban.

However for Māori women with breast cancer outcomes are worse than for urban Māori. Rural Māori women do have lower rates of screen detected cancer and higher rates of metastatic disease. Overall there is a suggestion that both their breast cancer-specific mortality rate and all-cause mortality rate are not improved compared with urban Māori and may even be over 40% worse. One possible explanation for this is that deprivation may be more of an issue for Māori living in rural areas compared with non-Māori women which may have an additionally deleterious effect on survival. Similar observations have been reported from the USA. In one study socio-economic deprivation for native American Indians appeared to be more important than rurality \[[@B12-ijerph-13-01000]\] while in another study rural black American women were less likely to be screened and had more advanced disease at diagnosis \[[@B13-ijerph-13-01000]\]. Within New Zealand we know that there are health system barriers for Māori women with breast cancer. These include access to primary care and that when accessing specialist care lack of transport was a barrier---a key factor for rural women \[[@B14-ijerph-13-01000]\]. Access to primary care is important in that it has been shown that the more general practitioners per population, the earlier stage of diagnosis \[[@B15-ijerph-13-01000]\].

These findings are similar to those of our previous study using cancer registry data which showed no difference in stage or survival in rural women after adjustment for demographic factors. The screen detection rates in our rural women are re-assuring and suggest that our breast screening programs in Auckland and the Waikato are reaching rural women. The main concern is the overall lower rate in Māori women. These disparities are being addressed by Breast-screen Aoteoaroea. We have shown that rural Māori women can achieve high rates of breast screening if a concerted general practice based approach is taken to encouraging mammographic screening \[[@B16-ijerph-13-01000]\]. One of the factors that has been noted in Australia linked to poorer outcomes has been that rural women may be treated in a smaller centre by a low case load surgeon \[[@B17-ijerph-13-01000]\]. This is not a factor in our study as all women were treated in a high case load centre either in Auckland or Waikato. This may be one explanation for the lack of difference in overall outcomes.

The strengths of this study are that it is based on data from complete and high quality registers which have been collected prospectively. The weakness is that the study is dominated by the high number of urban women and relatively small numbers of rural Māori (311) which mean the results relating to Māori are less stable than the remainder of the results.

5. Conclusions {#sec5-ijerph-13-01000}
==============

The study shows that, rather than being concerned that more needs to be done for rural women in general, it is rural Māori women where we need to make extra efforts to improve the later stage at diagnosis and ensure optimum treatment if we are to achieve equity in outcomes.
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###### 

Characteristics of urban and rural women.

  Characteristics         Rural         Urban   Total   *p*-Value (Chi-Square Test)                    
  ----------------------- ------------- ------- ------- ----------------------------- -------- ------- --
  **Age Groups**          **\<0.001**                                                                  
  \<40                    126           5.3%    669     6.8%                          795      6.5%    
  40--49                  401           17.0%   2263    22.9%                         2664     21.7%   
  50--59                  626           26.5%   2689    27.2%                         3315     27.1%   
  60--69                  600           25.4%   2233    22.6%                         2833     23.1%   
  70--79                  364           15.4%   1178    11.9%                         1542     12.6%   
  80+                     247           10.4%   853     8.6%                          1100     9.0%    
  **Cancer Stage**        **0.066**                                                                    
  I                       997           42.2%   4291    43.4%                         5288     43.2%   
  II                      890           37.6%   3643    36.9%                         4533     37.0%   
  III                     345           14.6%   1514    15.3%                         1859     15.2%   
  IV                      132           5.6%    437     4.4%                          569      4.6%    
  **Grade**               **\<0.001**                                                                  
  1                       557           25.3%   2270    24.1%                         2827     24.4%   
  2                       1113          50.5%   4281    45.5%                         5394     46.5%   
  3                       535           24.3%   2850    30.3%                         3385     29.2%   
  Unknown                 159                   484                                   643              
  **Tumour Size (mm)**    **0.238**                                                                    
  0--20                   1123          51.7%   4726    50.3%                         5849     50.5%   
  20+                     1050          48.3%   4674    49.7%                         5724     49.5%   
  Unknown                 191                   485                                   676              
  **Mode of Detection**   **0.909**                                                                    
  Not screen detected     1458          61.7%   6084    61.5%                         7542     61.6%   
  Screen detected         906           38.3%   3801    38.5%                         4707     38.4%   
  **ERPR**                **0.034**                                                                    
  ER and PR negative      395           17.1%   1840    19.0%                         2235     18.7%   
  ER and/or PR positive   1910          82.9%   7819    81.0%                         9729     81.3%   
  Unknown                 59                    226                                   285              
  **Ethnicity**           **\<0.001**                                                                  
  NZ European             1932          82.2%   6943    71.2%                         8875     73.3%   
  Māori                   311           13.2%   844     8.7%                          1155     9.5%    
  Pacific                 38            1.6%    759     7.8%                          797      6.6%    
  Asian                   47            2.0%    920     9.4%                          967      8.0%    
  Others                  22            0.9%    285     2.9%                          307      2.5%    
  Unknown                 14                    134                                   148              
  **Total**               2364          100%    9885    100%                          12,249   100%    

ER: Estrogen receptor; RP: Progesterone receptor; NZ: New Zealand.
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###### 

Urban and rural women Māori and NZ European.

  Characteristics                         Māori         NZ European                                                                     
  --------------------------------------- ------------- ------------- ----- ------- ------ ------- ------ ------- ------ ------- ------ -------
  **Age Groups**                                                                                                                        
  ***p*-Value (Chi-Square Test) 0.043**   **\<0.001**                                                                                   
  \<40                                    23            7.4%          74    8.8%    97     8.4%    95     4.9%    407    5.9%    502    5.7%
  40--49                                  66            21.2%         238   28.2%   304    26.3%   303    15.7%   1391   20.0%   1694   19.1%
  50--59                                  100           32.2%         264   31.3%   364    31.5%   488    25.3%   1796   25.9%   2284   25.7%
  60--69                                  82            26.4%         183   21.7%   265    22.9%   491    25.4%   1650   23.8%   2141   24.1%
  70--79                                  29            9.3%          72    8.5%    101    8.7%    324    16.8%   926    13.3%   1250   14.1%
  80+                                     11            3.5%          13    1.5%    24     2.1%    231    12.0%   773    11.1%   1004   11.3%
  **Cancer Stage**                                                                                                                      
  ***p*-Value (Chi-Square Test) 0.076**   **0.178**                                                                                     
  I                                       112           36.0%         315   37.3%   427    37.0%   837    43.3%   3136   45.2%   3973   44.8%
  II                                      112           36.0%         313   37.1%   425    36.8%   726    37.6%   2546   36.7%   3272   36.9%
  III                                     53            17.0%         162   19.2%   215    18.6%   279    14.4%   1003   14.4%   1282   14.4%
  IV                                      34            10.9%         54    6.4%    88     7.6%    90     4.7%    258    3.7%    348    3.9%
  **Grade**                                                                                                                             
  ***p*-Value (Chi-Square Test) 0.065**   **\<0.001**                                                                                   
  1                                       56            19.7%         181   22.5%   237    21.7%   469    26.0%   1673   25.4%   2142   25.5%
  2                                       158           55.6%         384   47.6%   542    49.7%   905    50.1%   3009   45.6%   3914   46.6%
  3                                       70            24.6%         241   29.9%   311    28.5%   432    23.9%   1911   29.0%   2343   27.9%
  Unknown                                 27                          38            65             126            350            476    
  **Tumour Size (mm)**                                                                                                                  
  ***p*-Value (Chi-Square Test) 0.033**   **0.949**                                                                                     
  0--20                                   130           48.0%         322   40.6%   452    42.4%   945    52.9%   3497   52.9%   4442   52.9%
  20+                                     141           52.0%         472   59.4%   613    57.6%   843    47.1%   3109   47.1%   3952   47.1%
  Unknown                                 40                          50            90             144            337            481    
  **Mode of detection**                                                                                                                 
  ***p*-Value (Chi-Square Test) 0.323**   **0.960**                                                                                     
  Not screen detected                     208           66.9%         538   63.7%   746    64.6%   1170   60.6%   4209   60.6%   5379   60.6%
  Screen detected                         103           33.1%         306   36.3%   409    35.4%   762    39.4%   2734   39.4%   3496   39.4%
  **ERPR**                                                                                                                              
  ***p*-Value (Chi-Square Test) 0.389**   **0.124**                                                                                     
  ER and PR negative                      55            18.0%         131   15.8%   186    16.4%   324    17.2%   1275   18.8%   1599   18.4%
  ER and/or PR positive                   251           82.0%         696   84.2%   947    83.6%   1558   82.8%   5518   81.2%   7076   81.6%
  Unknown                                 5                           17            22             50             150            200    
  **Total**                               311           100%          844   100%    1155   100%    1932   100%    6943   100%    8875   100%

ER: Estrogen receptor; RP: Progesterone receptor; NZ: New Zealand.
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###### 

5-year and 10-year breast cancer-specific survival and all-cause survival by Kaplan--Meier method.

  Groups                                5-Year (95% CI)   10-Year (95% CI)   Log Rank Test (*p*-Value)                    
  ------------------------------------- ----------------- ------------------ --------------------------- ---------------- -------
  **Breast cancer-specific survival**                                                                                     
  Rural women                           86.6%             (85.1%--88.1%)     81.5%                       (79.6%--83.4%)   0.211
  Urban women                           88.0%             (87.3%--88.7%)     82.5%                       (81.5%--83.4%)   
  Rural Māori women                     78.3%             (73.2%--83.5%)     72.1%                       (65.8%--78.5%)   0.072
  Urban Māori women                     84.1%             (81.4%--86.8%)     77.9%                       (74.2%--81.5%)   
  Rural European women                  87.9%             (86.3%--89.4%)     82.7%                       (80.7%--84.8%)   0.605
  Urban European women                  88.6%             (87.8%--89.4%)     83.0%                       (81.9%--84.1%)   
  **All-cause survival**                                                                                                  
  Rural women                           80.6%             (78.9%--82.3%)     67.8%                       (65.4%--70.2%)   0.007
  Urban women                           82.7%             (81.9%--83.4%)     71.2%                       (70.1%--72.4%)   
  Rural Māori women                     71.6%             (66.2%--77.0%)     55.8%                       (48.2%--63.3%)   0.017
  Urban Māori women                     77.9%             (74.9%--80.9%)     64.9%                       (60.6%--69.2%)   
  Rural European women                  81.9%             (80.0%--83.7%)     69.0%                       (66.4%--71.6%)   0.394
  Urban European women                  82.0%             (81.1%--83.0%)     70.3%                       (69.0%--71.7%)   
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###### 

Hazard ratio for mortality estimated by Cox proportional hazards model.

  Groups                                                    Unadjusted Hazard Ratio (95% CI)   Adjusted Hazard ^1^ Ratio (95% CI)          
  --------------------------------------------------------- ---------------------------------- ------------------------------------ ------ -----------------
  **Breast cancer-specific mortality**                                                                                                     
  Rural women compared with urban women                     1.08                               (0.96--1.22)                         1.01   (0.87--1.17)
  Rural Māori women compared with urban Māori women         1.31                               (0.97--1.76)                         1.47   (1.00--2.16)
  Rural European women compared with urban European women   1.04                               (0.90--1.19)                         0.94   (0.79--1.10)
  **All-cause mortality**                                                                                                                  
  Rural women compared with urban women                     1.13                               (1.03--1.24) \*                      1.04   (0.94--1.16)
  Rural Māori women compared with urban Māori women         1.33                               (1.05--1.68) \*                      1.43   (1.08--1.91) \*
  Rural European women compared with urban European women   1.05                               (0.94--1.16)                         0.90   (0.80--1.02)

^1^ Adjusted for age, (ethnicity), cancer stage, tumour size, grade, hormonal status (ERPR), year of diagnosis, mode of detection and comorbidity. \* *p*-Value \< 0.05.
